WHO Drug Information Vol
Total Page:16
File Type:pdf, Size:1020Kb
WHO Drug Information Vol. 32, No. 4, 2018 WHO Drug Information Contents ICDRA ATC/DDD classification 509 18th International Conference of Drug Regulatory 551 ATC/DDD classification (temporary) Authorities (ICDRA) Recommendations 556 ATC/DDD classification (final) Consultation documents International Nonproprietary Names (INN) 519 The International Pharmacopoeia 519 Revision of the monograph on ethinylestradiol 530 Polymorphism 559 List N° 120 of Proposed International Nonproprietary 538 Revision of the monograph on levofloxacin 546 Revision of the monograph on levofloxacin tablets Names (INN) for Pharmaceutical Substances Abbreviations and websites CHMP Committee for Medicinal Products for Human Use (EMA) EMA European Medicines Agency (www.ema.europa.eu) European Union EU FDA U.S. Food and Drug Administration (www.fda.gov) Health Canada Federal department responsible for health product regulation in Canada (www.hc-sc.gc.ca) HPRA Health Products Regulatory Authority, Ireland (www.hpra.ie ) HSA Health Sciences Authority, Singapore (www.hsa.gov.sg) ICDRA International Conference of Drug Regulatory Authorities ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use IGDRP (www.ich.org) International Generic Drug Regulators Programme (https://www.igdrp.com) MHLW Ministry of Health, Labour and Welfare, Japan MHRA Medicines and Healthcare Products Regulatory Agency, United Kingdom (www.mhra.gov.uk) Medsafe New Zealand Medicines and Medical Devices Safety Authority (www.medsafe.govt.nz) Ph. Int The International Pharmacopoeia (http://apps.who.int/phint/) Pharmacovigilance Risk Assessment Committee (EMA) PRAC Pharmaceuticals and Medical Devices Agency, Japan (www.pmda.go.jp/english/index.htm) PMDA Swissmedic Swiss Agency for Therapeutic Products (www.swissmedic.ch) TGA Therapeutic Goods Administration, Australia (www.tga.gov.au) U.S. United States of America WHO World Health Organization (www.who.int) WHO Essential medicines and health products (www.who.int/medicines/en/) WHO EMP WHO Prequalification team (https://extranet.who.int/prequal/) WHO PQT Note: The online version of this issue (freely available at www.who.int/medicines/publications/druginformation) has direct clickable hyperlinks to the documents and websites referenced 18th ICDRA recommendations ICDRA 18th International Conference of Drug Regulatory Authorities “Smart Safety surveillance: A life-cycle approach to promoting safety of medical products” The 18th International Conference of Drug Regulatory Authorities (ICDRA) was held in Dublin, Ireland from 3 to 7 September 2018. The event was co- hosted by the Health Products Regulatory Authority (HPRA) of Ireland and the World Health Organization (WHO). More than 300 delegates from regulatory authorities of WHO Member States participated in the 18th ICDRA. The recommendations as presented at the end of the conference are set out on the following pages. They are reproduced here as provided by the moderators in the closing plenary sessions and finalized following the consultations with the participants. Feedback, particularly from non-participating authorities, is welcome. Several common cross-cutting themes emerged from the discussions. These can be further grouped and consolidated and include e.g. promoting regulatory collaboration, convergence and harmonization throughout the products life cycle; improving coordination, risk-based prioritization of investments, reliance, work- sharing and use of regional networks; promoting greater transparency, awareness and communication; enabling regulatory preparedness for public health emergencies; enabling access to innovative medical products; development of international standards; and provision of technical assistance to support implementation. WHO intends to further develop a more concise iteration of these recommendations in the form of a work plan, integrating any feedback received and ensuring greater alignment and consistency across the various work streams. This work plan will be prepared in 2019, and the outcomes of the deliverables will be presented to the 19th ICDRA in 2020. ► 18th ICDRA website: http://www.icdra2018.ie Information on past ICDRA conferences is available at: www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/en/ 509 WHO Drug Information Vol. 32, No. 4, 2018 18th ICDRA recommendations THEME: Regulatory collaboration, convergence and harmonization Recommendations to WHO Recommendations to Member States 1. Regulatory collaboration, 1. When sharing assessment or convergence and harmonization inspection reports, Member States activities should incorporate not only should share unredacted reports, initial authorization but also life- where possible, which is important to cycle management and build trust and to optimize reliance on pharmacovigilance. outcomes from other regulators. 2. WHO should provide a toolbox with all the available options for regulatory collaboration, convergence and harmonization and increase awareness to facilitate selection of the appropriate mechanisms by member states. THEME: Certification of Pharmaceutical Products (CPP) Recommendations to WHO 1. WHO should advocate for the use of an electronic CPP template by issuing and receiving authorities to expedite the process and mitigate against any further need for “legalization.” 2. WHO should advocate for the CPP standard procedure specifying that value-added, unredacted documents either accompany the CPP or are provided upon request by any receiving agency. 3. The CPP template should be updated to reflect current manufacturing situations by including: (a) the sites of manufacture with addresses, and (b) a reminder that the receiving country should check that the product being shipped to it is exactly the same as the product being certified by the issuing country. 510 18th ICDRA recommendations WHO Drug Information Vol. 32, No. 4, 2018 THEME: Regulatory preparedness for public health emergencies) Recommendations to WHO Recommendations to Member States 1. WHO should facilitate communication 1. Member States should consider the between stakeholders (manufacturers feasibility of “conditional approvals” for of IVDs, vaccines and therapeutics) and PHE products with strengthened regulators on needs for products, pharmacovigilance and long-term development work and risk assessment monitoring after outbreaks. work. This should be facilitated by WHO setting up a pre-Emergency Use Listing scheme. 2. WHO should encourage the use of regulatory networks such as ICMRA in the case of public health emergencies and should support effective transition from emergency use to in-country approval. THEME: Enabling access to innovative medical products in resource-limited settings Recommendations to WHO Recommendations to Member States 1. WHO is asked to rapidly finalize the 1. While fully recognizing that there are good regulatory practice suite of different languages and different guidance, with a particular focus on regulatory systems, Member States are developing practical advice options, urged to review their current application and best practices to promote dossier formats to ensure that all regulatory collaboration and reliance requirements are scientifically justified for the whole lifecycle management of and better aligned with internationally medical products, both for individual agreed harmonized standards. National Regulatory Authorities and for regional networks. 2. WHO is asked to use its position in the various international regulatory harmonization forums to help promote alignment of regulatory application dossier formats, including elimination of unnecessary differences in the national and regional CTD requirements. 511 WHO Drug Information Vol. 32, No. 4, 2018 18th ICDRA recommendations THEME: Benchmarking of Regulatory Systems: towards mature regulatory systems 4. Further clarify the role of WHO Listed Recommendations to WHO Authorities at Maturity Level 3 or 1. Continue support for regulatory Maturity Level 4 and describe how this systems strengthening to Member information can be utilized by Member States utilizing the Global States to support and advance their Benchmarking Tool which has proven regulatory work. to be effective in promoting one global standard for regulatory systems. Recommendations to Member States 1. Invest resources to strengthen 2. Support regulatory systems regulatory systems utilizing the Global strengthening to Member States at Benchmarking Tool and work towards different maturity levels in a strategic attaining at least Maturity Level 3 while manner. implementing principle of continuous improvement for all maturity levels. 3. Further develop the process for designating WHO Listed Authorities 2. Explore approaches to utilize concept of with input from Member States. reliance and collaborative decision- making to increase timely access to safe and effective medical products. THEME: Future direction of WHO Prequalification (PQT) Recommendations to WHO Recommendations to Member States 1. Recognizing PQP’s demonstrated 1. Member states should where possible effective contribution to UHC by take advantage of opportunities offered facilitating access to quality assured by WHO through its Prequalification medical products, WHO should expand Programme by signing up and using the the scope of products eligible for PQ collaborative registration procedures assessment and diversify the pathways and utilizing the practical training and to PQ product listing to include capacity building opportunities offered